We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+25.17%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$14.8B
AUM Growth
+$1.58B
Cap. Flow
-$1.22B
Cap. Flow %
-8.22%
Top 10 Hldgs %
44.34%
Holding
132
New
32
Increased
38
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$317M
2
CRM icon
Salesforce
CRM
+$270M
3
TMO icon
Thermo Fisher Scientific
TMO
+$259M
4
MDCO
Medicines Co
MDCO
+$221M
5
PPLI
People Inc
PPLI
+$137M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.55B
2
BRMK
Broadmark Realty Capital Inc. Common Stock
BRMK
+$754M
3
AABA
Altaba Inc
AABA
+$666M
4
BABA icon
Alibaba
BABA
+$196M
5
CTXS
Citrix Systems Inc
CTXS
+$183M

Sector Composition

Rank Sector Weight
1 Healthcare 38.48%
2 Communication Services 11.12%
3 Technology 9.77%
4 Industrials 5.05%
5 Financials 3.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INFO
26
DELISTED
IHS Markit Ltd. Common Shares
INFO
$207M 1.4%
2,743,550
-831,834
-23% -$59.2M
ASND icon
27
Ascendis Pharma A/S
ASND
$16B
$178M 1.2%
1,279,000
-271,000
-17% -$30.1M
SPGI icon
28
S&P Global
SPGI
$122B
$175M 1.18%
640,382
-191,932
-23% -$49.9M
GD icon
29
General Dynamics
GD
$103B
$173M 1.17%
981,365
-10,367
-1% -$1.86M
IOVA icon
30
Iovance Biotherapeutics
IOVA
$1.93B
$173M 1.17%
6,250,000
+225,000
+4% +$5.12M
ALNY icon
31
Alnylam Pharmaceuticals
ALNY
$29.5B
$167M 1.13%
1,450,000
-50,000
-3% -$4.98M
MYOK
32
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$149M 1.01%
2,050,000
+19,603
+1% +$1.19M
EXEL icon
33
Exelixis
EXEL
$13.8B
$132M 0.89%
7,500,000
+5,750,000
+329% +$97.5M
TRU icon
34
TransUnion
TRU
$15.3B
$131M 0.88%
1,527,771
+272,633
+22% +$22.7M
ENTA icon
35
Enanta Pharmaceuticals
ENTA
$377M
$108M 0.73%
1,750,000
+475,788
+37% +$29.5M
XLRN
36
DELISTED
Acceleron Pharma
XLRN
$106M 0.72%
2,000,000
-400,000
-17% -$18.2M
BRMK
37
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$91.5M 0.62%
7,174,613
-67,825,387
-90% -$754M
BMY.RT
38
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$91.4M 0.62%
+30,374,950
New +$79M
EFX icon
39
Equifax
EFX
$20.5B
$91.4M 0.62%
652,189
+17,133
+3% +$2.37M
ZGNX
40
DELISTED
Zogenix, Inc.
ZGNX
$91.2M 0.62%
1,750,000
– –
AMRN
41
Amarin Corp
AMRN
$297M
$88.4M 0.6%
206,250
+106,220
+106% +$40.3M
AXE
42
DELISTED
Anixter International Inc
AXE
$84.5M 0.57%
+917,893
New +$74.4M
ZYME icon
43
Zymeworks
ZYME
$1.6B
$77.3M 0.52%
1,700,000
-31,500
-2% -$1.14M
QGEN icon
44
Qiagen
QGEN
$8.73B
$72.8M 0.49%
+2,031,342
New +$75.5M
GRFS
45
Grifois
GRFS
$5.35B
$72.5M 0.49%
3,113,222
– –
BOLD
46
DELISTED
Audentes Therapeutics, Inc
BOLD
$71.2M 0.48%
+1,190,000
New +$44.7M
AGIO icon
47
Agios Pharmaceuticals
AGIO
$1.89B
$59.7M 0.4%
+1,250,000
New +$47.2M
GBT
48
DELISTED
Global Blood Therapeutics, Inc.
GBT
$59.6M 0.4%
750,000
-862,069
-53% -$51.1M
CCXI
49
DELISTED
ChemoCentryx, Inc.
CCXI
$59.3M 0.4%
1,500,000
-513,396
-25% -$9.01M
DCPH
50
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$59.1M 0.4%
950,000
+200,000
+27% +$9.51M
1
2
3 4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Farallon Capital Management held 132 positions worth $14.8B, up 12% from $13.2B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Farallon Capital Management withdrew a net $1.22B in Q4 2019, closing 16 positions and reducing 29 holdings. Its most notable exit was Celgene Corp, an estimated $1.55B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 40% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Farallon Capital Management opened a new position in Salesforce worth $281M.

  • Farallon Capital Management's largest Q4 2019 buy was Salesforce: 1,724,880 shares worth $281M.
  • Farallon Capital Management added most to Allergan plc in Q4 2019, an estimated $317M increase.
  • Farallon Capital Management's biggest Q4 2019 reduction was Broadmark Realty Capital Inc. Common Stock, cutting an estimated $754M.
  • Farallon Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $1.55B.
  • Farallon Capital Management's ten largest holdings make up 44% of its $14.8B portfolio in Q4 2019.
  • Farallon Capital Management opened 32 new positions and closed 16 in Q4 2019.
  • Farallon Capital Management's portfolio value rose 12% quarter-over-quarter to $14.8B.

Based on Farallon Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.